Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Korro Bio (KRRO) Current Deferred Revenue (2019 - 2025)

Historic Current Deferred Revenue for Korro Bio (KRRO) over the last 5 years, with Q3 2025 value amounting to $3.3 million.

  • Korro Bio's Current Deferred Revenue rose 5138.57% to $3.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $3.3 million, marking a year-over-year increase of 5138.57%. This contributed to the annual value of $3.5 million for FY2024, which is N/A changed from last year.
  • Per Korro Bio's latest filing, its Current Deferred Revenue stood at $3.3 million for Q3 2025, which was up 5138.57% from $3.9 million recorded in Q2 2025.
  • In the past 5 years, Korro Bio's Current Deferred Revenue registered a high of $9.4 million during Q1 2021, and its lowest value of $2.2 million during Q3 2024.
  • Over the past 3 years, Korro Bio's median Current Deferred Revenue value was $3.4 million (recorded in 2024), while the average stood at $4.2 million.
  • As far as peak fluctuations go, Korro Bio's Current Deferred Revenue tumbled by 7565.03% in 2021, and later surged by 5138.57% in 2025.
  • Quarter analysis of 3 years shows Korro Bio's Current Deferred Revenue stood at $9.4 million in 2021, then tumbled by 62.7% to $3.5 million in 2024, then decreased by 5.15% to $3.3 million in 2025.
  • Its Current Deferred Revenue was $3.3 million in Q3 2025, compared to $3.9 million in Q2 2025 and $2.8 million in Q1 2025.